Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.

abstract：:We treated 101 patients with advanced (stage III and IV) lymphosarcoma and reticulosarcoma at first presentation of the disease or in relapse according to a protocol combining initial chemotherapy, complementary radiotherapy on icebergs, supplementary chemotherapy, and, finally, active immunotherapy. The overall compl...

journal_title：Cancer chemotherapy and pharmacology

authors： Misset JL,Mathé G,Tubiana M,Caillou B,de Vassal F,Pouillart P,Gil M,Tentas C,Hayat M,Schwarzenberg L,Jasmin C,Delgado M,Machover D,Ribaud P,Musset M

更新日期：1978-01-01 00:00:00

abstract：PURPOSE:S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Kim HM,Bang S,Park JY,Seong J,Song SY,Chung JB,Park SW

更新日期：2009-02-01 00:00:00

abstract：:Some of 66 patients with head and neck tumors were treated with high-dose methotrexate monochemotherapy. The use of a prospective mathematical model with pharmacokinetic surveillance proved to be reliable, practical, and useful. By this means chemotherapy could be individualized, with a resultant marked reduction in t...

journal_title：Cancer chemotherapy and pharmacology

authors： Favre R,Monjanel S,Alfonsi M,Pradoura JP,Bagarry-Liegey D,Clement S,Imbert AM,Lena N,Colonna d'Istria J,Cano JP,Carcassonne Y

更新日期：1982-01-01 00:00:00

abstract：:Erratum to: Cancer Chemother Pharmacol (2014), 74:1139–1147, DOI 10.1007/s00280‑014‑2586‑6. Unfortunately, the part of acknowledgement detail was omitted in the published article and the below line must be considered as the last sentence: "This study is a Turkish Oncology Group trial". ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ozdemir N,Abali H,Vural M,Yalcin S,Oksuzoglu B,Civelek B,Oguz D,Bostanci B,Yalcin B,Zengin N

更新日期：2015-07-01 00:00:00

abstract：:A total of 2,238 new cancer patients were treated in our institution in 1988; among the 423 (18.9%) who were greater than 70 years old, 51 underwent chemotherapy. The median age was 75.8 years, and the Karnofsky performance status (KPS) was greater than or equal to 70% for 40 patients. Malignancies were hematopoietic ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bécouarn Y,Bui BN,Brunet R,Ravaud A

更新日期：1991-01-01 00:00:00

abstract：:Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5...

journal_title：Cancer chemotherapy and pharmacology

authors： Zucchetti M,D'Incalci M,Willems Y,Cavalli F,Sessa C

更新日期：1988-01-01 00:00:00

abstract：:Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular carcinoma. The use of structural analogues and derivatives of sorafenib has enabled the elucidation of critical targets and mechanism(s) of cell death for human cancer lines. We previously performed a st...

journal_title：Cancer chemotherapy and pharmacology

authors： Wecksler AT,Hwang SH,Liu JY,Wettersten HI,Morisseau C,Wu J,Weiss RH,Hammock BD

更新日期：2015-01-01 00:00:00

abstract：PURPOSE:The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists', clinicians' but also patients'...

journal_title：Cancer chemotherapy and pharmacology

authors： Heshe D,Hoogestraat S,Brauckmann C,Karst U,Boos J,Lanvers-Kaminsky C

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Metastatic bladder cancer is a serious condition with a 5-year survival rate of approximately 14 %, a rate that has remained unchanged for almost three decades. Thus, there is a profound need to identify the driving mutations for these aggressive tumors to better determine appropriate treatments. Mutational ...

journal_title：Cancer chemotherapy and pharmacology

authors： Cirone P,Andresen CJ,Eswaraka JR,Lappin PB,Bagi CM

更新日期：2014-03-01 00:00:00

abstract：PURPOSE:A standard chemotherapy regimen for neuroendocrine carcinoma of the gastrointestinal tract (GI-NEC) has not been established. Treatment usually consists of platinum doublets, consistent with the standard treatment for small-cell lung cancer (SCLC), with which it shares clinicopathological similarities. Here, we...

journal_title：Cancer chemotherapy and pharmacology

authors： Asayama M,Fuse N,Yoshino T,Yano T,Tahara M,Doi T,Fujii S,Ohtsu A

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors. PATIENTS AND METHODS:We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in ter...

journal_title：Cancer chemotherapy and pharmacology

authors： Torrisi R,Balduzzi A,Ghisini R,Rocca A,Bottiglieri L,Giovanardi F,Veronesi P,Luini A,Orlando L,Viale G,Goldhirsch A,Colleoni M

更新日期：2008-09-01 00:00:00

abstract：:The purpose of the present study was to determine the maximally tolerated dose of thioTEPA given with fixed high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous bone marrow (ABM) with or without granulocyte colony-stimulating factor (G-CSF)-primed peripheral-blood progenitor cells (PBPCs) in pa...

journal_title：Cancer chemotherapy and pharmacology

authors： Hussein AM,Petros WP,Ross M,Vredenburgh JJ,Affrontil ML,Jones RB,Shpall EJ,Rubin P,Elkordy M,Gilbert C,Gupton C,Egorin MJ,Soper J,Berchuck A,Clarke-Person D,Berry DA,Peters WP

更新日期：1996-01-01 00:00:00

abstract：UNLABELLED:Hypericin, a polycyclic aromatic dianthroquinone, is a natural pigment derived from the plant Hypericum perforatum (St John's Wort). The compound has been synthesized and shown to inhibit the growth of malignant glioma cell lines in vitro via inhibition of protein kinase C. Oral hypericin has entered clinica...

journal_title：Cancer chemotherapy and pharmacology

authors： Fox E,Murphy RF,McCully CL,Adamson PC

更新日期：2001-01-01 00:00:00

abstract：PURPOSE:Several studies have identified amino acid residues located on the hydrophobic side of the helix that forms transmembrane domain 6 (TM6) of the ABC transporter P-glycoprotein (Pgp) as being important for function. The purpose of this study was to determine if alterations to residues on the hydrophilic side coul...

journal_title：Cancer chemotherapy and pharmacology

authors： Song J,Melera PW

更新日期：2001-11-01 00:00:00

abstract：:Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent wit...

journal_title：Cancer chemotherapy and pharmacology

authors： Israel M,Karkowsky AM,Khetarpal VK

更新日期：1981-01-01 00:00:00

abstract：PURPOSE:To determine the safety, the maximal tolerated dose, and to assess for any clinical activity of pomalidomide given to patients with advanced solid tumors. PATIENTS AND METHODS:Patients with incurable solid tumors were enrolled. Two different dosing schedules were explored. In Cohort A patients were given pomal...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Nock C,Bokar J,Krishnamurthi S,Gibbons J,Rodal MB,Ness A,Remick SC,Dreicer R,Dowlati A

更新日期：2012-11-01 00:00:00

abstract：:Anthracyclines are important antitumor agents used in the treatment of solid tumors, lymphomas, and acute lymphoblastic as well as myelocytic leukemias. The clinical utility of agents such as doxorubicin and daunorubicin and their well-characterized cardiotoxicity have prompted many efforts to develop analogs that ret...

journal_title：Cancer chemotherapy and pharmacology

authors： Kuffel MJ,Reid JM,Ames MM

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:To investigate the activity of combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin in patients with metastatic urothelial cancer. METHODS:A group of 29 patients were treated with 2000 mg/m2 ifosfamide, 750 mg/m2 5-fluorouracil, 100 mg/m2 etoposide and 20 mg/m2 cisplatin. All four ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukui I,Yonese J,Tsukamoto T,Yoshida T,Kim T,Tohma T,Ishiwata D

更新日期：2001-07-01 00:00:00

abstract：PURPOSE:Polyamines are absolutely essential for maintaining tumor cell proliferation. PG-11047, a polyamine analogue, is a nonfunctional competitor of the natural polyamine spermine that has demonstrated anticancer activity in cells and animal models of multiple cancer types. Preclinical investigations into the effects...

journal_title：Cancer chemotherapy and pharmacology

authors： Murray Stewart T,Von Hoff D,Fitzgerald M,Marton LJ,Becerra CHR,Boyd TE,Conkling PR,Garbo LE,Jotte RM,Richards DA,Smith DA,Stephenson JJ Jr,Vogelzang NJ,Wu HH,Casero RA Jr

更新日期：2021-01-01 00:00:00

abstract：PURPOSE:Tamoxifen is a key therapeutic option for breast cancer treatment. Understanding its complex metabolism and pharmacokinetics is important for dose optimization. We examined the possibility of utilizing archival formalin-fixed paraffin-embedded (FFPE) tissue as an alternative sample source for quantification sin...

journal_title：Cancer chemotherapy and pharmacology

authors： Ng ES,Kangarloo SB,Konno M,Paterson A,Magliocco AM

更新日期：2014-03-01 00:00:00

abstract：:Sparsomycin is a cytotoxic drug exhibiting a broad spectrum of in vitro activity against murine tumors and many tumor cell lines. It also appears to be a potent stimulator of the antitumor activity of cisplatin against L1210 leukemia in vivo. However, because of its toxicity, the antitumor activity of sparsomycin on m...

journal_title：Cancer chemotherapy and pharmacology

authors： Zylicz Z,Wagener DJ,Fernandez del Moral P,van Rennes H,Wessels JM,Winograd B,van der Kleijn E,Vree TB,van Haelst U,van den Broek LA

更新日期：1987-01-01 00:00:00

abstract：:A dose-ranging study with oral levonantradol was performed in 20 cancer patients. The optimum oral dose which attenuated vomiting accompanying chemotherapy was 1 mg 4-hourly. Side-effects comprised dizziness, confusion, euphoria, drowsiness, and difficulty in concentrating. There was no cardiovascular toxicity. Overal...

journal_title：Cancer chemotherapy and pharmacology

authors： Welsh J,Stuart F,Sangster G,Milstead R,Kaye S,Cash H,Charlton D,Calman K

更新日期：1983-01-01 00:00:00

abstract：:Equimolar doses of chlorambucil and melphalan (both 10 mg/kg) were administered i.v. to anesthetized rats, and the plasma and brain concentrations of chlorambucil, its metabolites 3,4-dehydrochlorambucil and phenylacetic mustard, and melphalan were determined by high-performance liquid chromatography from 5 to 240 min...

journal_title：Cancer chemotherapy and pharmacology

authors： Greig NH,Sweeney DJ,Rapoport SI

更新日期：1988-01-01 00:00:00

abstract：:Antibodies can be used to target cancer therapies to malignant tissue; the approach is attractive because conventional treatments such as chemo- and radiotherapy are dose limited due to toxicity in normal tissues. Effective targeting relies on appropriate pharmacokinetics of antibody-based therapeutics, ideally showin...

journal_title：Cancer chemotherapy and pharmacology

authors： Chester KA,Mayer A,Bhatia J,Robson L,Spencer DI,Cooke SP,Flynn AA,Sharma SK,Boxer G,Pedley RB,Begent RH

更新日期：2000-01-01 00:00:00

abstract：:The pharmacokinetics of diacetyldianhydrogalactitol (DADAG) was compared in mice, rats, and humans. The ratios of human therapeutic dose (ThD) to the LD10 were 8 and 5 in mice and rats, respectively. The ratios of the corresponding AUCs of DADAG were 20 and 17, whereas those of dianhydrogalactitol (DAG), the main, act...

journal_title：Cancer chemotherapy and pharmacology

authors： Kerpel-Fronius S,Erdélyi-Tóth V,Somfai-Relle S,Csetényi J,Kovács P,Ujj G,Kanyár B

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:Amsalog, a derivative of 9-aminoacridine, is an inhibitor of topoisomerase II. Early studies of intravenous amsalog administered either once weekly, or daily for 3 days repeated every 3 weeks, showed that myelosuppression is the dose-limiting toxicity (DLT). Phase II studies showed only limited activity in brea...

journal_title：Cancer chemotherapy and pharmacology

authors： Fyfe D,Price C,Langley RE,Pagonis C,Houghton J,Osborne L,Woll PJ,Gardner C,Baguley BC,Carmichael J,Cancer Research Campaing Phase I\/II Trials Committee.

更新日期：2001-04-01 00:00:00

abstract：:Plasma and tissue levels of doxorubicin (DXR) and doxorubicinol (DXR-OL) were measured fluorometrically after high-pressure liquid chromatography at 1, 3, and 24 h following one, nine, and 24 doses of 1.0 mg DXR/kg or one and eight doses of 4.0 mg DXR/kg, IP, to rats. Comparison of plasma levels of DXR found following...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters JH,Gordon GR,Kashiwase D,Acton EM

更新日期：1981-01-01 00:00:00

abstract：:In recent years significant progress in the understanding of the immune biology of melanoma has evolved from the identification of melanoma antigens (MAs) recognized by T cells. MAs consist of intracellular proteins that are expressed on the surface of cancer cells in association with human leukocyte antigen (HLA) cla...

journal_title：Cancer chemotherapy and pharmacology

authors： Nielsen MB,Marincola FM

更新日期：2000-01-01 00:00:00

abstract：:A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen JB,Bach F,Dombernowsky P,Hansen HH

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:The chimeric protein BCR-ABL, a constitutively active protein-tyrosine kinase, triggers downstream signalling proteins, such as STAT3, ultimately resulting in the survival of myeloid progenitors in BCR-ABL-positive leukemias. Here, we evaluated the effect of LLL-3, an inhibitor of STAT3 activity, on cell viabil...

journal_title：Cancer chemotherapy and pharmacology

authors： Mencalha AL,Du Rocher B,Salles D,Binato R,Abdelhay E

更新日期：2010-05-01 00:00:00